{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:32:34Z","timestamp":1783402354442,"version":"3.54.6"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>X-linked hypophosphatemia (XLH) is a rare, progressive, genetic disease with multisystem impact that typically begins to manifest in early childhood. Two treatment options exist: oral phosphate in combination with active vitamin D (\u201cconventional therapy\u201d) and a fully human monoclonal anti-FGF23 antibody, burosumab. The clinical benefit of conventional therapy in adults is limited, and poor tolerance and complications are common. Burosumab was first approved as a treatment for XLH in 2018 and its disease-modifying benefits in clinical trials in children suggest burosumab treatment could also alter the disease course in adults. Without long-term clinical data on multiple XLH-related sequelae available, the results of an elicitation exercise are reported, in which eight global experts in XLH posited how long-term treatment with burosumab is anticipated to impact the life course of clinical sequelae in adults with XLH. Based on their clinical experiences, the available evidence and their disease understanding, the experts agreed that some long-term benefits of using burosumab are likely in adults with XLH even if they have a misaligned skeleton from childhood. Burosumab treatment is anticipated to reduce the incidence of fractures and halt the progression of clinical sequelae associated with conventional therapy. While the trajectories for established dental abscesses are not expected to improve with burosumab treatment, dental abscess development may be prevented. Starting treatment with burosumab in childhood to increase the likelihood of an aligned skeleton and continuation into and throughout adulthood to maintain euphosphatemia may optimize patient outcomes, although future real-world investigation is required to support this hypothesis.<\/jats:p>","DOI":"10.3389\/fendo.2023.1211426","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T08:06:55Z","timestamp":1689926815000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives"],"prefix":"10.3389","volume":"14","author":[{"given":"Lothar","family":"Seefried","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Biosse","family":"Duplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Briot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Florenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Kassim","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne M.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1095-130","article-title":"A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets","volume":"11","year":"1995","journal-title":"Nat Genet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23","volume":"26","year":"2000","journal-title":"Nat Genet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2018-205130","article-title":"Disorders of phosphate metabolism","volume":"72","author":"Leung","year":"2019","journal-title":"J Clin Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M207872200","article-title":"Human fibroblast growth factor-23 mutants suppress na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production","volume":"278","author":"Saito","year":"2003","journal-title":"J Biol Chem"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2012.05.015","article-title":"FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1\/2-SGK1 signaling pathway","volume":"51","author":"Andrukhova","year":"2012","journal-title":"Bone"},{"key":"B7","article-title":"X-Linked hypophosphatemia","volume-title":"GeneReviews","author":"Ruppe","year":"2017"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-021-02156-x","article-title":"Potential influences on optimizing long\u2212term musculoskeletal health in children and adolescents with x\u2212linked hypophosphatemia (XLH)","volume":"17","author":"Glorieux","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.340","article-title":"A clinician\u2019s guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-020-01136-8","article-title":"Pulp chamber features, prevalence of abscesses, disease severity, and PHEX mutation in X-linked hypophosphatemic rickets","volume":"39","author":"Baroncelli","year":"2021","journal-title":"J Bone Miner Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-018-0147-6","article-title":"Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations","volume":"41","author":"Chesher","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-021-00841-4","article-title":"Characterization of oral health status in Chilean patients with X-linked hypophosphatemia","volume":"109","author":"Marin","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab739","article-title":"Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data","volume":"2021","author":"Javaid","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30426-7","article-title":"Approach to patients with hypophosphataemia","volume":"8","author":"Florenzano","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13023-016-0538-4","article-title":"Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia","volume":"11","author":"Forestier-Zhang","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms","volume":"174","author":"Che","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-021-05875-w","article-title":"Clinical and molecular characterization of Chilean patients with X-linked hypophosphatemia","volume":"32","author":"Jimenez","year":"2021","journal-title":"Osteoporos Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J Endocr Soc"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/coa.13825","article-title":"Characterization of otologic involvement in patients with X-linked hypophosphatemia","volume":"46","author":"Ivanovic-Zuvic","year":"2021","journal-title":"Clin Otolaryngol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00662-x","article-title":"Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia","volume":"18","author":"Trombetti","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199112263252604","article-title":"Effects of therapy in X-linked hypophosphatemic rickets","volume":"325","author":"Verge","year":"1991","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr Connect"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030036","article-title":"Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets","volume":"88","author":"Makitie","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.75.3.1517380","article-title":"A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets","volume":"75","author":"Sullivan","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/jbmr.4486","article-title":"An expert perspective on phosphate dysregulation with a focus on chronic hypophosphatemia","volume":"37","author":"Aljuraibah","year":"2022","journal-title":"J Bone Miner Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01170-7","article-title":"Complications of phosphate and vitamin d treatment in X-linked hypophosphataemia","volume":"37","author":"Arango Sancho","year":"2020","journal-title":"Adv Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00338","article-title":"Nephrocalcinosis and nephrolithiasis in X-linked hypophosphatemic rickets: diagnostic imaging and risk factors","volume":"3","author":"Colares Neto","year":"2019","journal-title":"J Endocr Soc"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.06.025","article-title":"Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients","volume":"127","author":"DeLacey","year":"2019","journal-title":"Bone"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"B32","article-title":"Kyowa kirin announces European commission (EC) approval of CRYSVITA\u00ae (burosumab) for the treatment of X-linked hypophosphataemia (XLH) in older adolescents and adults","author":"Kirin","year":"2020"},{"key":"B33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0304-3959(83)90143-4","article-title":"Development of the Wisconsin brief pain questionnaire to assess pain in cancer and other diseases","volume":"17","author":"Daut","year":"1983","journal-title":"Pain"},{"key":"B34","article-title":"The WOMAC knee and hip osteoarthritis indices: development, validation, globalization and influence on the development of the AUSCAN hand osteoarthritis indices","volume":"23","author":"Bellamy","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial","volume":"34","author":"Insogna","year":"2019","journal-title":"J Bone Miner Res"},{"key":"B36","article-title":"Guidance note for lead authors of the IPCC fifth assessment report on consistent treatment of uncertainties","author":"Mastrandrea","year":"2010"},{"key":"B37","volume-title":"NICE DSU technical support document 13: identifying and reviewing evidence to inform the conceptualisation and population of cost-effectiveness models","author":"Kaltenthaler","year":"2011"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/1524839919890869","article-title":"Development of conceptual models to guide public health research, practice, and policy: synthesizing traditional and contemporary paradigms","volume":"21","author":"Brady","year":"2020","journal-title":"Health Promot Pract"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0525-1","article-title":"Informing reimbursement decisions using cost-effectiveness modelling: a guide to the process of generating elicited priors to capture model uncertainties","volume":"35","author":"Bojke","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2020-0734","article-title":"Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets","volume":"34","author":"Harada","year":"2021","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-011-9502-4","article-title":"An atypical degenerative osteoarthropathy in hyp mice is characterized by a loss in the mineralized zone of articular cartilage","volume":"89","author":"Liang","year":"2011","journal-title":"Calcif Tissue Int"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-022-00989-7","article-title":"The enthesopathy of XLH is a mechanical adaptation to osteomalacia: biomechanical evidence from hyp mice","volume":"111","author":"Macica","year":"2022","journal-title":"Calcif Tissue Int"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab282","article-title":"Incidence of complications in 25 adult patients with X-linked hypophosphatemia","volume":"106","author":"Kato","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa064","article-title":"Osteoarthritis, osteophytes, and enthesophytes affect biomechanical function in adults with X-linked hypophosphatemia","volume":"105","author":"Steele","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-004-1504-z","article-title":"Hearing impairment in familial X-linked hypophosphatemic rickets","volume":"163","author":"Fishman","year":"2004","journal-title":"Eur J Pediatr"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.01.013","article-title":"Qualitative research to explore the patient experience of X-linked hypophosphatemia and evaluate the suitability of the BPI-SF and WOMAC(R) as clinical trial end points","volume":"21","author":"Theodore-Oklota","year":"2018","journal-title":"Value Health"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107681","article-title":"FGF23 deficiency leads to mixed hearing loss and middle ear malformation in mice","volume":"9","author":"Lysaght","year":"2014","journal-title":"PloS One"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4443","article-title":"Conductive hearing loss in the hyp mouse model of X-linked hypophosphatemia is accompanied by hypomineralization of the auditory ossicles","volume":"2021","author":"Delsmann","year":"2021","journal-title":"J Bone Miner Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1210\/en.2012-1551","article-title":"Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice","volume":"153","author":"Karaplis","year":"2012","journal-title":"Endocrinology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.591417","article-title":"Impact of early conventional treatment on adult bone and joints in a murine model of X-linked hypophosphatemia","volume":"8","author":"Cauliez","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa242","article-title":"Enthesopathy, osteoarthritis, and mobility in X-linked hypophosphatemia","volume":"105","author":"Imel","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1210\/en.2018-00184","article-title":"FGF23 regulates wnt\/beta-catenin signaling-mediated osteoarthritis in mice overexpressing high-Molecular-Weight FGF2","volume":"159","author":"Meo Burt","year":"2018","journal-title":"Endocrinology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab739","article-title":"Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data","volume":"107","author":"Javaid","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-0825.2006.01326.x","article-title":"Dentin structure in familial hypophosphatemic rickets: benefits of vitamin d and phosphate treatment","volume":"13","author":"Chaussain-Miller","year":"2007","journal-title":"Oral Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2020.107597","article-title":"Insights into dental mineralization from three heritable mineralization disorders","volume":"212","author":"Chavez","year":"2020","journal-title":"J Struct Biol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2015-2199","article-title":"Conventional therapy in adults with X-linked hypophosphatemia: effects on enthesopathy and dental disease","volume":"100","author":"Connor","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10672","article-title":"Burosumab and dental abscesses in children with X-linked hypophosphatemia","author":"Gadion","year":"2022","journal-title":"JBMR Plus"},{"key":"B58","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/S13023-020-01434-4","article-title":"The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study","volume":"15","author":"Padidela","year":"2020","journal-title":"Orphanet J Rare Dis"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1211426\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T08:07:02Z","timestamp":1689926822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1211426\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":58,"alternative-id":["10.3389\/fendo.2023.1211426"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1211426","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"article-number":"1211426"}}